Royalty Pharma PE ratio RPRX
Share price divided by earnings per share over the last twelve months, since 2021.
- Today, Nov 3, 2026
- 38.2×
- 6-year median
- 20.5×
- Against its 6-year history
- 99th
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 10.9× to 38.2×
- Peer median
- 38.4×
Royalty Pharma's PE ratio is 38.2× as of Nov 3, 2026: a share price of $67.30 against $1.76 of earnings per share over the last twelve months.
That is above its 6-year median of 20.5×, higher than on 99% of days in the last 6 years.
Over that time it ranged from 10.9× in Dec 2024 to 38.2× in Oct 2026.
The median for 10 healthcare stocks of a similar size is 38.4×.
PE ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 37.8× | 23.7× | 38.2× |
| 2025 | 23.9× | 11.3× | 24.4× |
| 2024 | 11.2× | 10.9× | 23.6× |
| 2023 | n/m a value too high to mean anything | ||
| 2022 | 22.1× | 19.8× | 22.8× |
| 2021 | 20.6× | 14.3× | 35.8× |
Against its peers
Companies in Healthcare nearest Royalty Pharma's size, closest first, today.
| Company | PE ratio |
|---|---|
| RPRXRoyalty Pharma | 38.2× |
| BIIBBiogen | 44.3× |
| GEHCGE HealthCare Technologies | 18.3× |
| ONCBeOne Medicines | 63.2× |
| IQVIQVIA | 32.0× |
| ZTSZoetis | 13.7× |
| ILMNIllumina | 44.0× |
| MTDMettler-Toledo International | 38.4× |
| RMDResMed | 21.4× |
| WATWaters | 118× |
| MDLNMedline | n/m |
| Peer median | 38.4× |
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on Royalty Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.